We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations
The latest strains have spread fast and governments are trying to catch up
Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements
New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain
‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants
US prepares to roll out jabs to last age group without access once regulatory approval is received
The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven
German biotech’s promising early-stage results make it a sought-after partner
German biotech maintains guidance but prepares for fall in sales because of jab oversupply
Remuneration at the three big jab makers reflects surge in value of share options
German biotech plans to boost R&D spending by 50% as quarterly earnings beat forecasts
Johnson government announces plan after similar moves in Scotland and Wales
First human study of variant-specific jab by big western drugmaker could prompt shift in manufacturing
Hopes early warning system will give policymakers and vaccine producers more time to address health risks
Drugmakers set to take on GSK as they aim to replicate Covid jab success
Long the poor relation to Frankfurt, Mainz aims to cash in on ‘priceless advertising’ offered by biotech group
Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant
Drugmakers are stress-testing existing jabs while preparing new formulas
WHO says differing predictions from Oxford, BioNTech and Moderna are ‘premature’
Combating coronavirus could end up resembling a game of whack-a-mole
German biotech expects to hit €17bn in sales and produce 3bn jabs this year
Hesitancy high as regulators authorise BioNTech/Pfizer Covid-19 vaccine for 5 to 11 year olds
US expected to become first country to authorise vaccine for younger children
Rwanda and Senegal agreement a big step in plans to produce Covid jabs on the continent
Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare
International Edition
